SCHEMBL26554177

SCHEMBL26554177

CCCCCCCCCCc1ccc2oc(CCCNC(=O)OC(C)(C)C)nc2c1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.49
LMNA P02545 3/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
GAA P10253 2/20 0.47
POLB P06746 1/20 0.47
NPSR1 Q6W5P4 2/20 0.46
MAPT P10636 1/20 0.45
ATM Q13315 1/20 0.45
RAB9A P51151 2/20 0.45
NPC1 O15118 1/20 0.42
ALDH1A1 P00352 2/20 0.42
TP53 P04637 2/20 0.42
HPGD P15428 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
PKM P14618 1/20 0.41
MAPK1 P28482 1/20 0.41
USP2 O75604 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29437076 0.98 TSHR (0.52) TSHRLMNAMEN1KMT2AGAA
SCHEMBL26554184 0.98 TSHR (0.52) TSHRLMNAMEN1KMT2AGAA
SCHEMBL26554128 0.95 LMNA (0.46) TSHRLMNAMEN1KMT2AGAA
SCHEMBL26554201 0.92 LMNA (0.49) TSHRLMNAMEN1KMT2AGAA
SCHEMBL29437065 0.92 LMNA (0.49) TSHRLMNAMEN1KMT2AGAA
SCHEMBL29437051 0.87 LMNA (0.46) TSHRLMNAMEN1KMT2AGAA
SCHEMBL26554197 0.87 LMNA (0.46) TSHRLMNAMEN1KMT2AGAA
SCHEMBL29437035 0.87 TSHR (0.46) TSHRLMNAMEN1KMT2AGAA
SCHEMBL29437003 0.87 TSHR (0.46) TSHRLMNAMEN1KMT2AGAA
SCHEMBL29437025 0.87 TSHR (0.43) TSHRLMNAMEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230331683-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. 2023-10-19 US disclosed
US-20230331683-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. 2023-10-19 US disclosed
EP-4211111-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY University of Virginia Patent Foundation (US) 2023-07-19 EP disclosed
WO-2022056045-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2022-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331683-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY SPNS2, SPCS2, SMN1; SMN2 TSHR 3498/4885LMNA 2726/4885MEN1 3339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.